Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367312 · ClinicalTrials.gov registry record · Phase 2
Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI
A Phase 2 study, sponsored by Bastiaan Driehuys.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03367312: Completed Phase 2 study, sponsored by Bastiaan Driehuys.
NCT03367312 is a Phase 2 study that has completed, run by Bastiaan Driehuys. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03367312, a Phase 2 study, has completed, sponsored by Bastiaan Driehuys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study seeks to deploy several forms of 129Xe MRI contrast as well as emerging conventional proton MRI techniques for imaging lung structure and perfusion. Specifically, the 129Xe MRI scans will provide 3D images of ventilation and gas exchange, and spectroscopic indices will be evaluated too test gas exchange dynamics with high temporal resolution. The conventional 1H MRi scans will include a free-breathing ultra-short echo time scan that provides images similar to that of a CT scan. This will be done pre, immediately post, and 2-4 hours post inhaled prostacyclin therapy.
Primary Outcome
Percent change in pulmonary gas exchange (percent change in abnormal RBC percentage - calculated as: 100\*(value at 3 hours - value at baseline)/value at baseline) in patients with PH treated with inhaled prostacyclin.
Interventions
- DRUG Hyperpolarized 129Xenon gas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
What the finished NCT03367312 record still lists
NCT03367312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Hyperpolarized 129Xenon gas is the first listed.
NCT03367312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03367312 about?
NCT03367312 is a clinical study titled "Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI". This study seeks to deploy several forms of 129Xe MRI contrast as well as emerging conventional proton MRI techniques for imaging lung structure and perfusion. Specifically, the 129Xe MRI scans will provide 3D images of ventilation and gas exchange, and spectroscopic indices will be evaluated too te...
What is the current status of trial NCT03367312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-03-29. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT03367312?
The interventions under investigation include: Hyperpolarized 129Xenon gas (DRUG).
Who is sponsoring clinical trial NCT03367312?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03367312's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI